Lexicon Pharma (LXRX) Announces EMA Acceptance of MAA for Sotagliflozin to Treat Adults With Type 1 Diabetes
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE